Who
Michael P. Bailey
Director
Company insider
Files Form 4 as: Director, Verastem; President & CEO, Aveo Pharmaceuticals; Sr. VP, Chief Comm. Officer, Madrigal Pharmaceuticals; SVP, Commercial Ops, Imclone Systems.
In numbers
- Trades disclosed
- 89
- Buys
- 2
- Sells
- 7
- Bought
- $187K
- Sold
- $1.0M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 1 Aug 2006
- Last trade
- 21 May 2026
- Last filed
- 27 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 27 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —108,000 at $0.00 | filing |
| 21 May 2026filed 27 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —108,000 at $0.00 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —3,249 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,999 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —7,499 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —90,000 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —46,000 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —75,366 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —99,999 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —16,750 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —93,500 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —35,302 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —275,100 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —625,192 | filing |
| 19 Jan 2023filed 19 Jan 2023 | Aveo Pharmaceuticals | SEC FORM 4 Code D | $5.0M333,167 at $15.00 | filing |
| 20 Dec 2022filed 22 Dec 2022 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —26,499 at $0.00 | filing |
| 20 Dec 2022filed 22 Dec 2022 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —85,722 at $0.00 | filing |
| 20 Dec 2022filed 22 Dec 2022 | Aveo Pharmaceuticalsoption or derivative | SEC FORM 4 Code M | —164,525 at $0.00 | filing |
| 20 Dec 2022filed 22 Dec 2022 | Aveo Pharmaceuticals | SEC FORM 4 Code M | $164K26,499 at $6.20 | filing |
| 20 Dec 2022filed 22 Dec 2022 | Aveo Pharmaceuticals | SEC FORM 4 Code M | $480K85,722 at $5.60 | filing |
News
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY)MDGL · themarketsdaily.com · 20 Oct 2026Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)MDGL · manilatimes.net · 15 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastMDGL · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Michael P. Bailey; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.